Innsbruck, Austria

Bart Spiesschaert

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Boehringer Ingelheim International Gmbh, Viratherapeutics Gmbh. Active years: 2026.


% Patents Active = 100.0


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Bart Spiesschaert: Innovator in Vector Technology

Introduction

Bart Spiesschaert is a notable inventor based in Innsbruck, Austria. He has made significant contributions to the field of biotechnology, particularly in the development of chimeric vectors. His innovative work has led to the filing of a patent that showcases his expertise and dedication to advancing medical technology.

Latest Patents

Bart Spiesschaert holds a patent for "VSV Chimeric Vectors." This invention represents a breakthrough in vector technology, which is crucial for various applications in gene therapy and vaccine development. His patent is a testament to his innovative approach and commitment to improving therapeutic methods.

Career Highlights

Throughout his career, Bart has worked with prominent companies in the biotechnology sector. He has been associated with Viratherapeutics GmbH and Boehringer Ingelheim International GmbH. His experience in these organizations has allowed him to hone his skills and contribute to significant advancements in the field.

Collaborations

Bart has collaborated with esteemed colleagues, including Guido Wollmann and Patrik Erlmann. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.

Conclusion

Bart Spiesschaert is a distinguished inventor whose work in vector technology has made a lasting impact on the biotechnology industry. His patent and collaborations reflect his commitment to advancing medical science and improving therapeutic solutions.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…